Phosphoramidate pronucleotides of cytostatic 6-aryl-7-deazapurine ribonucleosides.

[1]  Helena Zábranská,et al.  CycloSal‐phosphate Pronucleotides of Cytostatic 6‐(Het)aryl‐7‐deazapurine Ribonucleosides: Synthesis, Cytostatic Activity, and Inhibition of Adenosine Kinases , 2010, ChemMedChem.

[2]  R. Pohl,et al.  6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. , 2010, Journal of medicinal chemistry.

[3]  J. Balzarini,et al.  Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells , 2009, ChemMedChem.

[4]  J. Neyts,et al.  The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus. , 2009, Bioorganic & medicinal chemistry letters.

[5]  W. Parker.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. , 2009, Chemical reviews.

[6]  J. Balzarini,et al.  Successful kinase bypass with new acyclovir phosphoramidate prodrugs. , 2008, Bioorganic & medicinal chemistry letters.

[7]  William A. Lee,et al.  Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases , 2008, Molecular Pharmacology.

[8]  M. Erion,et al.  Prodrugs of phosphates and phosphonates. , 2008, Journal of medicinal chemistry.

[9]  C. Mcguigan,et al.  First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. , 2007, Journal of medicinal chemistry.

[10]  C. Mcguigan,et al.  Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. , 2007, Journal of medicinal chemistry.

[11]  William A. Lee,et al.  Cathepsin A Is the Major Hydrolase Catalyzing the Intracellular Hydrolysis of the Antiretroviral Nucleotide Phosphonoamidate Prodrugs GS-7340 and GS-9131 , 2006, Antimicrobial Agents and Chemotherapy.

[12]  C. Galmarini,et al.  Recent developments to improve the efficacy of cytotoxic nucleoside analogues. , 2006, Recent patents on anti-cancer drug discovery.

[13]  C. Meier.  cycloSal Phosphates as Chemical Trojan Horses for Intracellular Nucleotide and Glycosylmonophosphate Delivery — Chemistry Meets Biology , 2006 .

[14]  T Robak,et al.  Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. , 2005, Current cancer drug targets.

[15]  M. Otto,et al.  Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides. , 2005, Journal of medicinal chemistry.

[16]  J. Imbach,et al.  SATE pronucleotide approaches: an overview. , 2004, Mini reviews in medicinal chemistry.

[17]  C. Dumontet,et al.  Drug resistance to cytotoxic nucleoside analogues. , 2003, Current drug targets.

[18]  C. Schultz.  Prodrugs of biologically active phosphate esters. , 2003, Bioorganic & medicinal chemistry.

[19]  S. Johnson,et al.  Nucleoside analogues in the treatment of haematological malignancies , 2001, Expert opinion on pharmacotherapy.

[20]  Michal Hocek,et al.  Cytostatic 6-Arylpurine Nucleosides III. Synthesis and Structure-Activity Relationship Study in Cytostatic Activity of 6-Aryl-, 6-Hetaryl- and 6-Benzylpurine Ribonucleosides , 2001 .

[21]  Michal Hocek,et al.  Synthesis and cytostatic activity of substituted 6-phenylpurine bases and nucleosides: application of the Suzuki-Miyaura cross-coupling reactions of 6-chloropurine derivatives with phenylboronic acids. , 2000, Journal of medicinal chemistry.

[22]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.